An Update on the Immunotherapy for Oropharyngeal Squamous Cell Carcinoma

• Published in: Frontiers in oncology Vol. 12; p. 800315
• Main Authors: Huang, Yaxuan, Lan, Yunyun, Zhang, Zhe, Xiao, Xue, Huang, Tingting
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 15.03.2022
• Subjects: human papillomavirus infection; immune checkpoint inhibitor; immunotherapy; Medicin och hälsovetenskap; Oncology; oropharyngeal squamous cell carcinoma (OPSCC); treatment outcome; immune checkpoint inhibitor; oropharyngeal squamous cell carcinoma (OPSCC); treatment outcome; immunotherapy; human papillomavirus infection
• ISSN: 2234-943X; 2234-943X
• DOI: 10.3389/fonc.2022.800315

Oropharyngeal squamous cell carcinoma (OPSCC) is an uncommon malignancy worldwide. Remarkably, the rising incidence of OPSCC has been observed in many developed countries over the past few decades. On top of tobacco smoking and alcohol consumption, human papillomavirus (HPV) infection has become a major etiologic factor for OPSCC. The radiotherapy-based or surgery-based systemic therapies are recommended equally as first-line treatment, while chemotherapy-based strategy is applied to advanced diseases. Immunotherapy in head and neck squamous cell carcinoma (HNSCC) is currently under the spotlight, especially for patients with advanced diseases. Numerous researches on programmed death-1/programmed death-ligand 1 checkpoint inhibitors have proven beneficial to patients with metastatic HNSCC. In 2016, nivolumab and pembrolizumab were approved as the second-line treatment for advanced metastatic HNSCC by the USA Food and Drug Administration. Soon after, in 2019, the USA Food and Drug Administration approved pembrolizumab as the first-line treatment for patients with unresectable, recurrent, and metastatic HNSCC. It has been reported that HPV-positive HNSCC patients were associated with increased programmed death-ligand 1 expression; however, whether HPV status indicates different treatment outcomes among HNSCC patients treated with immunotherapy has contradicted. Notably, HPV-positive OPSCC exhibits a significantly better clinical response to primary treatment (i.e., radiotherapy, surgery, and chemotherapy) and a more desirable prognosis compared to the HPV-negative OPSCC. This review summarizes the current publications on immunotherapy in HNSCC/OPSCC patients and discusses the impact of HPV infection in immunotherapeutic efficacy, providing an update on the immune landscape and future perspectives in OPSCC.